Background: From the past decade to date, several studies related to O-(2-
[18F]fluoroethyl)-L-tyrosine (18F-FET) positron emission tomography (PET) in brain tumours
have been published in the literature.
Objective: The aim of this narrative review is to summarize the recent developments and
the current role of 18F-FET PET in brain tumours according to recent literature data.
Methods: Main findings from selected recently published and relevant articles on the role
of 18F-FET PET in neuro-oncology are described.
Results: 18F-FET PET may be useful in the differential diagnosis between brain tumours
and non-neoplastic lesions and between low-grade and high-grade gliomas. Integration of
18F-FET PET into surgical planning allows better delineation of the extent of resection
beyond margins visible with standard MRI. For biopsy planning, 18F-FET PET is particularly
useful in identifying malignant foci within non-contrast-enhancing gliomas. 18F-FET
PET may improve the radiation therapy planning in patients with gliomas. This metabolic
imaging method may be useful to evaluate treatment response in patients with gliomas
and it improves the differential diagnosis between brain tumours recurrence and posttreatment
changes. 18F-FET PET may provide useful prognostic information in high-grade
Conclusion: Based on recent literature data 18F-FET PET may provide additional diagnostic
information compared to standard MRI in neuro-oncology.